key: cord-0036485-fv9h4klj
authors: Meyer, Keith C.; Glanville, Allan R.
title: Bronchiolitis Obliterans Syndrome and Chronic Lung Allograft Dysfunction: Evolving Concepts and Nomenclature
date: 2013-06-14
journal: Bronchiolitis Obliterans Syndrome in Lung Transplantation
DOI: 10.1007/978-1-4614-7636-8_1
sha: 28961154326f33653b99879ebb2254933f94fbf7
doc_id: 36485
cord_uid: fv9h4klj

Bronchiolitis obliterans syndrome (BOS) eventually occurs in the majority of lung transplant recipients who survive beyond 1 year, can greatly impair quality of life, and is, directly or indirectly, the major cause of delayed allograft dysfunction and recipient death. A number of associated events or conditions are strongly associated with the risk for developing BOS; these include acute rejection, gastroesophageal reflux, infections, and autoimmune reactions that can occur in the setting of alloimmune responses to the lung allograft as recipients are given intense immunosuppression to prevent allograft rejection. The term chronic lung allograft dysfunction (CLAD) is being increasingly used to refer to recipients with late allograft dysfunction that meets the spirometric criteria for the diagnosis of BOS, but clinicians should recognize that such dysfunction can occur for a variety of reasons other than BOS. The recently identified entity of restrictive allograft syndrome, which is now recognized as a relatively distinct phenotype of CLAD, has features that differentiate it from classic obstructive BOS. A number of other entities that can also significantly affect allograft function must also be considered when significant allograft dysfunction is encountered following lung transplantation.

Late lung allograft dysfunction with progressive loss of function and graft loss was originally described for heart-lung transplant recipients in 1984 [ 1 ] . Histopathological postmortem examination of these lungs revealed lesions of constrictive bronchiolitis with airway fi brosis and luminal obliteration that was designated as obliterative bronchiolitis (OB). Late decline in allograft function following recovery and stabilization of lung function after the initial lung implantation was increasingly encountered as more lung transplants were performed in the late 1980s, and the consensus document that suggested that the term bronchiolitis obliterans syndrome (BOS) could be used to designate the syndrome of persistent loss of function with decline in FEV 1 that could not be explained by other, potentially reversible complications such as acute rejection or infection was published in 1993 [ 2 ] .

Clinical experience that evolved over the subsequent 2 decades of lung transplantation has confi rmed that the pathologic fi nding that usually correlates with a persistent decline in post-transplant FEV 1 that is consistent with the clinical diagnosis of BOS is the presence of the lesion of OB. The threshold of a ≥20 % decline in FEV 1 (with a pattern of airfl ow obstruction) from an established baseline was chosen in previous consensus documents [ 2 , 3 ] as an appropriate surrogate marker of OB due to the strong association of OB with late chronic allograft dysfunction. Major considerations that led to choosing FEV 1 as a surrogate marker were (1) the relative diffi culty of obtaining adequate diagnostic tissue via transbronchial lung biopsy (TBLB) plus (2) the desire to avoid the substantially increased risks of performing more invasive diagnostic procedures (i.e., surgical lung biopsy), although more extensive sampling of lung tissue could facilitate a more confi dent diagnosis (and may be considered necessary in certain situations). This chapter will provide an overview of current concepts pertaining to BOS and the terminology used to describe delayed or chronic allograft dysfunction.

Post-transplant OB is characterized by progressive obliteration of small airways accompanied by a persistent decline in FEV 1 , an obstructive spirometric pattern, an essentially clear chest radiograph, and the lack of an alternative diagnosis to explain a persistent decline in lung function [ 2 ] . This syndrome was presumed to be caused by chronic allograft rejection, and the term chronic lung allograft dysfunction (CLAD) was coined and used to refer to allograft dysfunction that met the criteria that were adopted to indicate a diagnosis of BOS. Previously published consensus statements have designated a persistent decline in FEV 1 to ≤80 % of baseline post-transplant FEV 1 (that is present for a minimum of 3 weeks in the absence of confounding conditions) as a surrogate marker of probable OB (Table 1. 1 ), and a staging system was devised to qualify the level of FEV 1 decline, which correlates fairly well with severity of allograft dysfunction. By defi nition, 3 or more months were required to have elapsed from the time of transplantation in order for the diagnosis of BOS to be made [ 2 , 3 ] . This qualifi cation was made to help distinguish BOS from non-BOS acute and/or subacute complications of lung transplantation as well as to take into account the time needed to establish both a baseline FEV 1 and a confi rmed decline in FEV 1 with FEV 1 measurements taken 3 weeks apart. Because of concern that the cutoff value for FEV 1 at 80 % of the best post-transplant value may be insensitive to early decline in allograft function due to early OB, stage BOS-0p (FEV 1 = 81-90 % of baseline and/or FEF 25-75 ≤ 75 % of baseline) was added to the staging system to signify "potential BOS" [ 3 ] . One problem with this scheme is the considerable variation in FEV 1 values that some recipients may have due to the timing and fl uctuation in spirometric measurements caused by various post-transplant complications that can prevent a recipient from achieving a graft function plateau with reasonably stable posttransplant FEV 1 values that accurately represent the zenith of attainable function. Such fl uctuation and the consequent inability to establish stable post-transplant lung function make it diffi cult, if not impossible, to identify an accurate baseline value. The identifi cation of other surrogate markers (e.g., biomarkers) that accurately refl ect pathological airway and/or parenchymal processes for which specifi c interventions should be considered is much needed.

A considerable number of risk factors have been associated with the development of BOS (Table 1. 2 ). BOS is widely perceived as the physiological surrogate of an immunologically mediated phenomenon due to many observations that include its association with acute cellular rejection [ 4 ] , the association with greater degrees of HLA mismatch with BOS risk [ 5 ] , and evolving evidence of the involvement of autoimmune pathways [ 6 ] and the interplay of alloimmune and autoimmune processes that can lead to allograft rejection [ 7 ] . Furthermore, lung histopathology in patients with BOS shows striking similarities to the OB that can occur in allogeneic bone marrow or stem cell transplant recipients as well as constrictive bronchiolitis in patients with connective tissue diseases [ 8 -10 ] , and these airway changes are perceived as alloimmune or autoimmune disorders, respectively. Nonetheless, although BOS is frequently equated with the term chronic rejection, various interventions, including intensifi ed immunosuppression, may have little or no effect on the progressive loss of allograft function that is usually observed in lung transplant recipients who develop BOS. However, some patients can have signifi cant clinical responses to alternative immunomodulatory therapies such as total lymphoid irradiation [ 11 ] , or extracorporeal photopheresis [ 12 ] , although these responses generally consist of stabilization or a decrease in the tempo of lung function loss over time and are unlikely to improve lung function (see Chap. 16 ). In addition to alloimmune and/or autoimmune phenomena associated with BOS, various "non-immune" mechanisms have been implicated as playing a role in BOS pathogenesis. Although often referred to as nonimmune, these events/phenomena likely trigger or potentiate innate immune responses, which may also trigger or intensify alloimmune or autoimmune responses. These mechanisms include injury caused by primary graft dysfunction (PGD), gastroesophageal refl ux (GER), and infections caused by viruses, bacteria, or fungi [ 13 -15 ] . These likely involve allograft injury combined with triggering of innate immune responses that may also trigger or potentiate alloimmune/adaptive immune responses PGD, which affects 10-25 % of all lung transplants and is a leading cause of early morbidity and mortality, represents a form of acute lung injury that is considered to occur largely as a consequence of the periods of ischemia and reperfusion as the donor lung is procured and then implanted in the recipient [ 16 -19 ] . Although a number of studies have not consistently linked PGD to BOS [ 20 -24 ] , more recent studies support a link between PGD and the development of BOS [ 25 -27 ] . Daud et al. [ 25 ] found a convincing association of PGD grade with increased risk of developing BOS Stage 1 using International Society for Heart and Lung Transplantation (ISHLT) consensus defi nitions for PGD, and a more recent analysis of outcomes by this group identifi ed a direct relationship between PGD severity at 24, 48, and 72 h post-transplant and increased risk of BOS [ 28 ] . The most severe grade of PGD (grade 3) at all three time points was associated with the highest risk of developing BOS (RR was 3.31 for grade 3 PGD at 24 h).

The presence of signifi cant GER (GER that is increased in frequency/severity over what is considered normal) increases the risk that refl uxate can be aspirated into the lower respiratory tract and has been linked to both subacute and chronic lung allograft dysfunction [ 29 -36 ] . Multiple studies have reported a high prevalence of an abnormal degree of GER among patients with advanced lung disease and patients referred for lung transplantation [ 37 , 38 ] . Approximately 70 % of patients who undergo transplant evaluation have some evidence of signifi cant GER [ 38 ] , and acid refl ux may worsen following transplantation [ 39 ] . Gastroparesis and/ or esophageal dysmotility may also be present and increase the risk of refl ux and microaspiration. A negative correlation was found between increasing severity of acid refl ux (as measured by 24-h pH study) and post-transplant FEV 1 [ 36 ] , and the presence of nonacid refl ux (as measured by impedance testing) was reported to increase the risk for BOS nearly threefold [ 33 ] . Refl uxed bile acids in BAL fl uid have been found to be increased in cross-sectional studies of patients with BOS [ 40 , 41 ] , and GER associated with aspiration of bile acids (bile acids detected in BAL) has been linked to BOS [ 40 ] , a signifi cantly increased risk of BOS onset [ 41 ] , and poor response to azithromycin therapy [ 42 ] . Recent studies in animal models of lung transplantation suggest that gastric aspiration might enhance allorecognition and promote lung allograft rejection [ 43 , 44 ] , and GER has been linked to collagen V sensitization and BOS in transplant recipients [ 45 ] .

Infections caused by viruses, bacteria, and fungi have been linked to risk for developing BOS (see Chap. 11 ). A large number of studies have linked pulmonary CMV infection to the subsequent development of BOS and/or diminished posttransplant survival [ 46 -52 ] . Prophylactic and preemptive strategies to prevent/treat CMV infection have signifi cantly reduced the incidence of CMV disease in lung transplant recipients [ 53 -56 ] , and retrospective studies of perioperative ganciclovir prophylaxis suggest that preventing CMV disease may delay the onset of BOS [ 57 -59 ] . However, a recently published prospective, single-center study reported an incidence of CMV pneumonitis of 21 % within 6 months of transplant (in a cohort of 231 recipients) despite short-course prophylaxis being given to high-risk recipients [ 52 ] . These investigators observed that CMV pneumonitis was associated with a signifi cantly increased risk of BOS (HR 2.19) and diminished survival (HR 1.89).

Interestingly, a prospective, randomized 11-center trial that examined the effects of 3 vs. 12 months of post-transplant valganciclovir prophylaxis for D+R−, D+R+, and D−R+ recipients showed that the 12-months prophylaxis strategy signifi cantly diminished the incidence of CMV infection (64 % vs. 10 %), CMV disease (32 % vs. 4 %), and disease severity without any signifi cant difference in rates of acute rejection, opportunistic infection, CMV UL97 ganciclovir-resistance mutations, or adverse events [ 60 ] . However, it remains unclear whether such prolonged prophylaxis can reduce risk for BOS.

Infection with other β(beta)-herpes viruses may also cause serious complications. The non-CMV β-herpes viruses include Epstein-Barr virus (EBV), herpes simplex virus (HSV), varicella zoster virus (VZV), and human herpes viruses 6 (HHV-6) and 7 (HHV-7). A prospective cohort study of 385 lung transplant recipients linked repetitive detection of EBV DNA in peripheral blood with the development of BOS [ 61 ] , and HHV-6 or HHV-7 infection has been associated with BOS [ 62 , 63 ] .

Infection with community-acquired respiratory viruses (CARV) can be asymptomatic, cause mild symptoms, cause signifi cant respiratory tract disease, or lead to acute respiratory insuffi ciency and death. Recovery of CARV (infl uenza A and B, respiratory syncytial virus, parainfl uenza viruses, rhinoviruses, enteroviruses, adenoviruses, human metapneumovirus, human coronavirus, and human bocavirus) during infections suspicious for CARV in lung transplant recipients can range from 34 to 66 % [ 64 -66 ] , and retrospective as well as recent prospective investigations have linked CARV infections with BOS risk [ 64 , 67 -73 ] .

Post-transplant bacterial infection is exceedingly common in recipients with prior septic lung disease (CF and non-CF bronchiectasis) and is a leading cause of death in recipients with established BOS. Botha et al. [ 74 ] reported that de novo allograft colonization with Pseudomonas aeruginosa was strongly associated with developing BOS within 2 years of transplant (23.4 % colonized vs. 7.7 % noncolonized), Vos et al. [ 75 ] reported that persistent Pseudomonas colonization was an even greater risk for BOS than de novo colonization, and Gottlieb et al. [ 76 ] found that persistent allograft Pseudomonas colonization in a cohort of 59 patients with CF signifi cantly increased the prevalence of BOS. Additionally, Vos et al. [ 77 ] reported that BAL bile acid levels, neutrophils, and IL-8 levels correlated significantly with Pseudomonas colonization and suggested that the presence of abnormal GER and microaspiration can lead to persistent colonization with Pseudomonas .

Invasive fungal infections can be an important cause of morbidity and mortality in lung transplant recipients. Valentine et al. [ 78 ] reported that the diagnosis of fungal pneumonia or pneumonitis in a cohort of 160 recipients was an independent predictor of BOS with a hazard ratio of 2.1 (95 % CI 1.1-4.0) for early (0-100 days post-transplant) and 1.5 (95 % CI 1.1-1.9) for late (≥1 year) fungal pneumonia on multivariate analysis. Another study of 201 recipients reported that Aspergillus colonization was independently associated (multivariate Cox regression analysis) with the subsequent development of BOS (HR = 1.81; 95 % CI 1.03-3.19) and BOSassociated mortality (HR = 2.57; 95 % CI 1. 19-5.55) . Additionally, recipients with new or persistent Aspergillus colonization after developing BOS had increased risk of progression to Stage 3 BOS or death [ 79 ] .

Recent observations also suggest that environmental exposures can lead to airway injury and obliteration in non-transplant patients [ 80 -82 ] , and higher ambient levels of pollutants have recently been linked to BOS in lung transplant recipients [ 83 ] . Additionally, airway ischemia caused by disruption of the bronchial circulation has also been suggested as a potential cause of BOS [ 84 ] . Because established OB displays variable evidence of infl ammation combined with evidence of heightened innate immune responses, alloimmune reactions, autoimmunity, and fi broproliferation with airway obliteration that leads to allograft airway remodeling and loss of function, OB likely represents a fi nal common endpoint for allograft bronchiolar injury that can be precipitated and/or driven by a variety of insults and mechanisms.

Over the past decade it has become increasingly recognized that many recipients with declining lung function consistent with FEV 1 criteria for BOS can respond to certain interventions (see Chaps. 12 , 14 , 15 , and 16 ) ( Table 1. 3 ). Macrolides and neo-macrolides such as the azalide, azithromycin, possess anti-infl ammatory effects and inhibit IL-8 production and neutrophil recruitment, suppress bronchial infl ammation, and prevent or modulate airway damage for a number of respiratory disorders [ 85 ] . Observations from many centers indicate that a substantial number of patients who develop clinical BOS respond to azithromycin and may have their lung function stabilized or signifi cantly improved (see Chap. 15 ), such that some patients may no longer meet FEV 1 criteria for BOS after responding to the drug [ 86 , 87 ] . Azithromycin appears to be capable of diminishing the risk of graft loss and recipient death when given to patients with established BOS [ 88 , 89 ] . Additionally, the recently published, randomized prospective, placebo-controlled clinical trial conducted by Vos et al. [ 90 ] suggested that prophylactic administration of azithromycin initiated shortly after transplantation can signifi cantly decrease the risk of developing BOS, although a signifi cant impact on survival was not shown over the relatively brief, 2-year evaluation period.

As mentioned above, abnormal GER is highly prevalent in patients with advanced lung disease and in lung transplant recipients [ 37 , 91 ] , and the prevalence may increase post-transplant [ 39 , 40 ] . Notably, abnormal acid GER has been strongly linked to risk for BOS (see Chap. 12 ). However, pharmacologic therapy with protonpump inhibitors (PPI), although such therapy can increase the pH of gastric secretions and relieve symptoms, may have little effect on GER [ 41 ] . Indeed, PPI therapy may have negligible effect on nonacid refl ux, which may contain bile acids that can be very injurious to the lung [ 40 , 92 ] . Because pharmacologic suppression of gastric acid secretion may not signifi cantly suppress abnormal GER (especially weakly acid or nonacid refl ux) and microaspiration, gastric fundoplication has been investigated to a considerable degree as a means of preventing lung transplant complications and as a treatment for BOS when refl ux appears to be present [ 93 -95 ] . One case series suggests that it may prevent the appearance of BOS or prevent its progression if abnormal GER is diagnosed in patients who have developed BOS [ 35 ] . Additionally, as with the improvement in FEV 1 that has been observed with azithromycin therapy, fundoplication has been reported to lead to improved lung function such that patients can revert to BOS Stage 0 [ 34 ] . In summary, it has become clear that lung function decline that is consistent with a diagnosis of BOS can stabilize in some patients and not lead to sustained, progressive deterioration in allograft function and graft loss. Allograft functional decline that is consistent with the onset of BOS may respond to azithromycin therapy or anti-refl ux surgery such that spirometric criteria for BOS are no longer met due to improved FEV 1 and clinical status. However, treatment of BOS with intensifi ed immunosuppression or other modalities remains relatively ineffective to date, and more research into the basic pathogenetic mechanisms, preventive strategies, and treatment interventions is greatly needed.

It seems logical to use the term CLAD to indicate a late or delayed, signifi cant decline in lung function that can be due to evolving OB as well as other causes of allograft dysfunction in the chronic setting. However, it should be recognized that CLAD (which is increasingly used to indicate a decline in FEV 1 that appears to meet criteria for BOS) may not necessarily be caused by "chronic rejection" that is mediated by classical alloimmune responses (see Chap. 3 ). Additionally, a number of processes may be operant simultaneously and contribute to declining allograft function. For example, the presence of signifi cant anastomotic dysfunction combined with OB. The ability to identify characteristics that identify subsets of lung transplant recipients who have allograft function decline that meets criteria for BOS but may have specifi c disease mechanisms, specifi c triggering events and pathways, or characteristics that predict benefi cial response to a specifi c treatment intervention can aid efforts to provide specifi c treatments and make key management decisions concerning specifi c therapies to treat BOS.

A cause of CLAD has been recently described that has characteristics that distinguish it from typical BOS/OB (Table 1.4 ) . Sato et al. [ 96 ] identifi ed 156/468 recipients transplanted from 1996 to 2009 who developed a clinical picture consistent with CLAD (defi ned as an irreversible decline in FEV 1 to <80 % of baseline), and 47 (30 %) of those diagnosed with CLAD displayed evidence of restriction (irreversible decline in total lung capacity [TLC] to <90 % of baseline) associated with thoracic imaging (HRCT) changes consistent with interstitial lung disease (ILD) and peripheral parenchymal lung fi brosis. This constellation of fi ndings was termed restrictive allograft syndrome (RAS). Survival was worse for patients with (RAS) vs. patients with typical BOS (541 vs. 1,421 days; p = 0.0003). Two other groups have also described a subset of BOS patients with features of restriction via pulmonary function testing. Verleden et al. [ 97 ] diagnosed CLAD in 71 of 294 recipients and found that 20 (28.2 %) patients had restrictive changes on pulmonary function testing; 17 of these 20 recipients had persistent parenchymal infi ltrates on HRCT, and multivariate analysis showed that a restrictive pattern on pulmonary function testing (decline in TLC in 15, decline in FEV 1 and FVC in 5 with restrictive FEV 1 /FVC ratio) was associated with worse survival. Woodrow et al. [ 98 ] also identifi ed a substantial number of recipients with CLAD who met the FEV 1 criterion for BOS and had evidence of restriction (47 of 62, 44 %) via spirometric testing (TLC data were not reported) showing forced vital capacity decline from baseline ≥20 %; however, the prevalence of parenchymal infi ltrates on HRCT was similar for the restrictive vs. obstructive groups that met BOS criteria, and survival did not differ between the groups.

A more recent analysis of recipient cohorts who developed BOS by Sato et al. [ 99 ] has shown that the detection of diffuse alveolar damage (DAD) on lung biopsy specimens may have important implications for both obstructive BOS and RAS. They reported that DAD was seen at least once on TBLB in 320/720 (44 %) recipients, and early DAD (≤3 months post-transplant) was associated with a significantly increased mortality risk. They also found that bilateral lung recipients with adequate pulmonary function testing to distinguish RAS from BOS had earlier onset of BOS if early DAD was detected. Additionally, late new-onset DAD (>90 days post-transplant) was a signifi cant risk factor for developing RAS. A review of temporal changes on lung biopsy in recipients with RAS showed that DAD tended to be followed by development of pleuroparenchymal fi broelastosis [ 100 ] . Additional characterization of a subset of patients showed that ground-glass opacities on HRCT correlated with DAD episodes, and such episodes were accompanied by a decline in lung function with subsequent stabilization during interval periods that correlated with allograft fi brosis [ 101 ] . The existence of distinct phenotypes on the basis of length of time from transplant to BOS development and the tempo of disease progression have been suggested in the literature. Those recipients with early-onset BOS may represent a group of patients that is prone to rapid progression and poor prognosis [ 20 , 25 , 102 , 103 ] . Median survival for recipients with acute-onset BOS has been noted to be 29 vs. 58 months for later, chronic-onset BOS [ 104 ] . Additionally, Burton et al. [ 105 ] found that progression of BOS from lower to higher grade increases the risk of mortality up to threefold, and a rapid decline in FEV 1 of >20 % has been associated with worse prognosis [ 106 ] . Brugiere et al. [ 107 ] found that recipients with earlyonset BOS had lower mean FEV 1 , need for supplemental oxygen, and poorer graft survival than those with later-onset BOS. These observations suggest that patients with early-onset BOS represent a subset of recipients that are at risk for a more rapid decline in lung function plus a higher incidence of graft failure and death as compared to patients with late-onset BOS. However, not all patients with rapidly declining lung function associated with BOS have relentless progression; some may stabilize despite an initial rapid BOS onset and FEV 1 decline [ 108 ] .

The presence of signifi cant bronchoalveolar lavage (BAL) neutrophilia that is often associated with high-resolution computed tomographic (HRCT) changes of probable cellular bronchiolitis in patients with FEV 1 decline that meets the criterion for BOS Stage >0 has been perceived as representing a variant of BOS. These individuals are likely to respond to azithromycin therapy [ 88 , 109 ] , and FEV 1 may improve such that the recipient no longer meets spirometric criteria for BOS. Indeed, this reversibility, should it occur in response to azithromycin, poses an issue in terms of classifying this entity as a phenotype or subtype of BOS if criteria for BOS Stage ≥1 or even BOS-0p are eventually no longer met due to a signifi cant therapeutic response. This phenomenon has been termed neutrophilic reversible allograft dysfunction (NRAD) [ 15 , 88 ] , and it has been suggested to represent a specifi c phenotype of CLAD. In contrast to NRAD, patients who meet BOS criteria but do not respond to azithromycin have been proposed to represent a fi broproliferative BOS phenotype [ 88 ] . Nonetheless, distinct phenotypes of BOS that are based upon specifi c risk factors or other parameters have yet to be fi rmly established, and azithromycin-unresponsive individuals may have signifi cant variation in their underlying histopathological changes from those who respond to azithromycin.

The data from Sato et al. [ 96 ] and Verleden et al. [ 97 ] indicate that recipients with RAS may comprise a relatively specifi c CLAD phenotype that is distinguishable from patients with the more common BOS pattern of airfl ow obstruction that is usually not associated with parenchymal infi ltrates. These observations suggest that HRCT imaging and lung volume determinations (and perhaps FVC and the FEV 1 /FVC ratio) can be useful to differentiate recipients with the RAS phenotype from those with a typical obstructive BOS pattern when spirometric criteria for the onset of BOS are met. However, OB lesions may be present in lung specimens from recipients who develop allograft dysfunction that is consistent with a RAS phenotype [ 96 ] .

The differential diagnosis of acute lung allograft dysfunction includes surgical complications, PGD, or hyperacute rejection. Early allograft dysfunction that occurs outside of the immediate postoperative period is generally caused by acute cellular rejection, lymphocytic bronchiolitis, or infection, but other entities such as vascular or humoral rejection, pleural effusion or empyema, or venous thromboembolism must be considered.

Similarly, the differential diagnosis of late or delayed chronic allograft dysfunction must include a considerable number of potential complications as discussed in Chap. 3 , and the recent observations discussed above suggest that imaging and the determination of lung volumes can differentiate graft dysfunction caused by RAS from classical obstructive BOS. Distinguishing between these entities may be important in decision making (e.g., considering early listing for retransplantation for RAS that is progressive and unresponsive to therapeutic interventions), as the prognosis associated with RAS appears to be signifi cantly worse than that associated with obstructive BOS. Additionally, HRCT imaging combined with a BAL differential cell count can identify changes (cellular bronchiolitis on HRCT, BAL neutrophilia) that identify patients with a high likelihood of having NRAD, which can improve with neo-macrolide therapy. As our knowledge of these evolving syndromes with their differing phenotypic characteristics advances, therapies may be identifi ed that provide benefi t for a specifi c subset of CLAD but may not have effi cacy for other phenotypes.

We suggest that delayed allograft dysfunction with a persistent decline in FEV 1 ≥ 10 % of baseline can be used as a threshold value to signify the likely onset of CLAD, and such an FEV 1 decline should trigger consideration of the various entities that could cause such a decline in graft function and appropriate diagnostic testing to determine the cause(s). Imaging should be performed, and HRCT with expiratory views may provide more useful information than a routine chest radiograph. Bronchoscopy with examination of bronchial anastomoses and performance of BAL and endoscopic lung biopsies is likely to provide useful information that can be combined with clinical presentation and physical examination, imaging, and pulmonary function studies to identify and/or rule out various potential causes of CLAD. If criteria for the diagnosis of BOS are met, the various risk factors associated with BOS should be considered and appropriate testing performed to determine the most likely etiology and identify treatments that are most likely to stabilize or possibly improve allograft function (e.g., anti-refl ux surgery for signifi cant GER). This evolving classifi cation scheme ( Fig. 1.1 ) needs to be validated, but its adoption would allow a more precise defi nition of terms used to describe delayed-onset allograft dysfunction and also convey the complexity of CLAD, set a lower threshold to investigate FEV 1 decline in the chronic setting (which may allow earlier diagnosis and interventions to preserve allograft function), and promote the evolving concept that distinct phenotypes of CLAD can be identifi ed that may have varying prognoses and responses to therapeutic interventions.

Our perception of chronic allograft dysfunction is changing. While the terms OB, BOS, CLAD, and chronic rejection have been frequently used as synonymous and pertaining to allograft function due to OB, we now recognize that what we have termed BOS up to the present is actually a heterogeneous entity (e.g., RAS vs. BOS) and that (1) the term CLAD may be a better term to use for delayed allograft dysfunction, (2) CLAD can be caused by a variety of entities that have an impact on allograft function, (3) BOS is one of a number of relatively distinct CLAD entities, and (4) BOS phenotypes may better be identifi ed according to time of onset posttransplant, rapidity of progression, underlying etiology (e.g., associated with GER, azithromycin-responsive), and response to therapies (e.g., azithromycin or antirefl ux surgery). We suggest that a new classifi cation system with precise defi nitions should be created for delayed allograft dysfunction (i.e., CLAD). Suggested defi nitions and characteristics of CLAD and its subcategories. *Decline in FEV 1 may be due to (probable cellular) bronchiolitis that can respond to azithromycin therapy such that FEV 1 signifi cantly improves or normalizes: predictors of an increased likelihood of improvement with azithromycin include BAL neutrophilia (≥15 % neutrophils) and HRCT changes consistent with bronchiolitis (tree-in-bud opacities, peribronchiolar infi ltrates, ±air trapping). CXR routine chest radiograph, FEF forced expiratory fl ow rate from 75 to 25 % of forced vital capacity, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, HRCT highresolution computed tomogram, PFT pulmonary function testing, TLC total lung capacity

Posttransplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplant recipients

A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation

Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria

Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of posttransplant baseline FEV1

Mismatches at the HLA-dr and HLA-b loci are risk factors for acute rejection after lung transplantation

IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants

Alloimmunityinduced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts

Bronchiolar disorders

People's Medical Publishing House

Fibrotic and sclerotic manifestations of chronic graft-versushost disease

The safety and effi cacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation

The effi cacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation

Chronic lung allograft rejection: mechanisms and therapy

Chronic allograft rejection: epidemiology, diagnosis, pathogenesis, and treatment

Obliterative bronchiolitis following lung transplantation: from old to new concepts?

Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: defi nition. A consensus statement of the International Society for Heart and Lung Transplantation

Reperfusion injury signifi cantly impacts clinical outcome after pulmonary transplantation

Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part v: predictors and outcomes

The effect of primary graft dysfunction on survival after lung transplantation

Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS)

Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome

Risk factors for the development of obliterative bronchiolitis after lung transplantation

The signifi cance of a single episode of minimal acute rejection after lung transplantation

Outcome of lung transplanted patients with primary graft dysfunction

Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome

Early posttransplant infl ammation promotes the development of alloimmunity and chronic human lung allograft rejection

Immunological link between primary graft dysfunction and chronic lung allograft rejection

Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome

Importance of chronic aspiration in recipients of heart-lung transplants

Upper gastrointestinal dysmotility in heart-lung transplant recipients

Gastroesophageal refl ux as a reversible cause of allograft dysfunction after lung transplantation

Non-acidic supraesophageal refl ux associated with diffuse alveolar damage and allograft dysfunction after lung transplantation: a case report

Gastroesophageal refl ux in bronchiolitis obliterans syndrome: a new perspective

Improved lung allograft function after fundoplication in patients with gastroesophageal refl ux disease undergoing lung transplantation

Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal refl ux disease

Gastroesophageal refl ux disease in lung transplant recipients

Prevalence of gastroesophageal refl ux in end-stage lung disease candidates for lung transplant

Gastro-oesophageal refl ux and aspiration in patients with advanced lung disease

Lung transplantation exacerbates gastroesophageal refl ux disease

Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation

Gastro-esophageal refl ux and gastric aspiration in lung transplant patients with or without chronic rejection

Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin

Repetitive gastric aspiration leads to augmented indirect allorecognition after lung transplantation in miniature swine

Chronic aspiration of gastric fl uid induces the development of obliterative bronchiolitis in rat lung transplants

Refl ux-induced collagen type v sensitization: potential mediator of bronchiolitis obliterans syndrome

Stanford experience with obliterative bronchiolitis after lung and heart-lung transplantation

Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation

Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors

Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation

Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation

Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis syndrome

Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation

Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction

Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir

Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation

A trial valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients

Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus; related events and bronchiolitis obliterans syndrome after lung transplantation

Ganciclovir for cytomegalovirus: a call for indefi nite prophylaxis in lung transplantation

Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized controlled trial

Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation

Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation

Human herpesvirus 6 in bronchoalveolar lavage fl uid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?

Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant

Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact

A single-season prospective study of respiratory viral infections in lung transplant recipients

Adenovirus infection in the lung results in graft failure after lung transplantation

Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death

Respiratory viruses and chronic rejection in lung transplant recipients

Parainfl uenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function

Community respiratory viral infection in adult lung transplant recipients

Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study

A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients

Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome

De novo or persistent pseudomonal airway colonization after lung transplantation: importance for bronchiolitis obliterans syndrome?

Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fi brosis

Airway colonization and gastric aspiration after lung transplantation: do birds of a feather block together?

Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome

Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome

Airway obstruction related to diacetyl exposure at microwave popcorn production facilities

The chronic effects of sulfur mustard exposure

Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan

The impact of traffi c air pollution on bronchiolitis obliterans syndrome and mortality after lung transplantation

Lung transplant airway hypoxia: a diathesis to fi brosis?

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

Anti-infl ammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection

Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome

Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?

Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

A randomized placebo-controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation

Pretransplant gastroesophageal refl ux compromises early outcomes after lung transplantation

The effect of refl ux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D

Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation

Antirefl ux surgery for patients with end-stage lung disease before and after lung transplantation

Antirefl ux surgery preserves lung function in patients with gastroesophageal refl ux disease and end-stage lung disease before and after lung transplantation

Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction

Survival determinants in lung transplant patients with chronic allograft dysfunction

Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation

Revisiting the pathologic fi nding of diffuse alveolar damage after lung transplantation

Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fi broelastosis

Progression pattern of restrictive allograft syndrome after lung transplantation

Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation

Mycophenolate mofetil reduces alveolar infl ammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation

Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?

Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome

Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients

Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival

Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome

Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation